Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to CombAct-HIB Concomitantly Administered With Engerix B Paediatric and OPV at 6, 10, and 14 Weeks of Age in South African Infants

Trial Profile

Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to CombAct-HIB Concomitantly Administered With Engerix B Paediatric and OPV at 6, 10, and 14 Weeks of Age in South African Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hepatitis B vaccine recombinant; Hib-DTaP vaccine; Poliovirus vaccine live oral
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Actual patient number (622) added as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top